Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25 USD | -0.16% | -0.87% | -18.30% |
05-10 | UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating | MT |
05-09 | Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.30% | 3.11B | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- ARWR Stock
- News Arrowhead Pharmaceuticals, Inc.
- UBS Adjusts Arrowhead Pharmaceuticals' Price Target to $78 From $80, Maintains Buy Rating